Braveheart Bio CDO Michele Anderson Receives Award, Buys Stock

What Happened Michele Anderson, Chief Development Officer of Braveheart Bio (BRVE), was awarded a 300,000-share derivative award on Aug 5, 2026 (reporting code A) and made an open-market purchase of 1,111 common shares on Aug 7, 2026 (reporting code P) at $18.00 per share, totaling $19,998. The award shows a $0.00 acquisition price (derivative instrument) and the purchase is a straightforward buy of company stock.

Key Details

• Transactions reported: Aug 5, 2026 — 300,000-share award (derivative) at $0.00; Aug 7, 2026 — open-market purchase of 1,111 shares at $18.00 ($19,998 total).
• Shares owned after transaction: not specified in the provided Form 4 excerpt.
• Footnote: 1/48th of the shares subject to the option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to continuous service.
• Filing timeliness: Form 4 filed on Aug 7, 2026 (no late filing indicated).

Context The 300,000-share entry is a derivative award (an option per the footnote) that vests monthly over 48 months and does not represent immediately tradeable shares. The separate open-market purchase of 1,111 shares is a direct buy and indicates the insider acquired additional common stock rather than selling. As always, insider buys can be interpreted as a positive signal but do not substitute for broader research.